^
Association details:
| Biomarker: | EGFR mutation + PD-L1 expression |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1032P - ML41256: Phase II study of atezolizumab (atezo) in combination with bevacizumab (beva) in advanced non-squamous non-small cell lung cancer (nsqNSCLC) patients (pts) pretreated with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs)
Published date:
09/05/2022
Excerpt:
ML41256 is an open-label, single-arm, phase II, multicenter study enrolled pts with PD-L1 ≥1%, EGFR+, Stage IIIB/IV nsqNSCLC after treatment failure of EGFR TKIs. All pts received atezo 1200mg and beva 15mg/kg q3w until progressive disease assessed per RECIST v1.1, unacceptable toxicity, or death....Of 19 evaluable pts, ORR and disease control rate were 15.8% and 68.4% (3 partial response and 10 stable disease). Median progression-free survival and time to response were 2.8m and 1.4 m.
Trial ID:
